Lei Jianping on May 17
Zhuozheng Medical Holdings Limited (hereinafter referred to as "Zhuozheng Medical") has submitted a prospectus to be listed on the Hong Kong Stock Exchange.
The annual revenue is 690 million
Founded in Shenzhen in 2012, Zhuozheng Medical adopts a new model of online and offline integrated services, operating nearly 30 physical outlets in Beijing, Shanghai, Guangzhou, Shenzhen, Chengdu, Chongqing, Wuhan, Changsha, Suzhou, Hangzhou and other cities.
Our services cover internal medicine and general medicine, surgery, obstetrics and gynaecology, paediatrics, dentistry, dermatology and medical aesthetics, ophthalmology, otolaryngology, personalized medical check-ups, day surgery, air transport, international referral and other categories.
From January to March 2024, Zhuozheng Medical acquired a total of 51.04% equity interest in Wuhan Shenlong Tianxia, which owns Wuhan Beidouxing Children's Hospital and two Wuhan clinics. Wuhan Shenlong Tianxia has become our non-wholly owned subsidiary with effect from March 28, 2024.
Patients who received services at AccolaMedic's healthcare service providers and/or online healthcare service platforms in China for the years ended 31 December 2021, 2022 and 2023
The total number of visits was 149,493, 162,393 and 201,335 respectively, and the total number of paying patient visits to Excellence Medical's medical service providers and/or online medical service platforms was 470,924, 529,829 and 733,397 respectively.
For the years ended 31 December 2021, 2022 and 2023, the return rate of patients was 71.1%, 75.7% and 78.2%, respectively.
According to the prospectus, Zhuozheng Medical's revenue in 2021, 2022, and 2023 will be 417 million yuan, 473 million yuan, and 690 million yuan respectively; The gross profit was 49.55 million yuan, 43.98 million yuan and 134 million yuan respectively.
In 2021, 2022, and 2023, Zhuozheng Medical's revenue from physical medical services will be 372 million yuan, 393 million yuan, and 592 million yuan respectively, accounting for 89.1%, 83%, and 85.8% respectively.
Zhuozheng Medical's operating profit in 2021, 2022, and 2023 will be -109 million yuan, -138 million yuan, and -66.93 million yuan respectively.
Zhuozheng Medical's losses in 2021, 2022, and 2023 will be 251 million yuan, 222 million yuan, and 353 million yuan respectively; The adjusted net loss was 102 million yuan, 123 million yuan and 43.57 million yuan respectively.
As of December 31, 2023, Zhuozheng Medical had cash and cash equivalents of $198 million.
The post-investment valuation is $510 million
The executive directors of Zhuozheng Medical are Wang Zhiyuan and Shi Yi; The non-executive directors are Cao Shaoshan, Zhang Xiangdong, Wei Guoxing, Ms. Chen Xiaohong and Hao Rui; The independent non-executive Directors are Ms. Chen Rui, Wang Yonggang, Wang Gaofei and Dr. Zhu Hengpeng.
Since its establishment, Zhuozheng Medical has received many financings:
Among them, in 2017, it received $35.29 million in Series C financing, with a cost per share of $3.7143 and a post-investment valuation of $146 million;
In September 2019, it raised $50 million at a cost per share of $5.6876 and a post-investment valuation of $290 million.
In August 2021, it raised $60 million at a cost of $8.8258 per share and was valued at $510 million post-investment.
腾讯与H Capital是股东
Cheuk Sing Ho持股为18.92%，曹少山持股为1.68%，Nineteen Seventy-Seven持股为1.45%，Distinct Partners I Limited持股为4.43%，Distinct Partners II Limited持股为3.96%；
Tencent holds 19.39% of the shares, H Capital holds 14.89% of the shares, Renshan Youshe Innovation and Technology (Hong Kong) holds 1.92% of the shares, Beijing Tiantu Xingbei Investment Center (Limited Partnership) holds 4.65% of the shares, and Chengdu Tiantu Tiantou Dongfeng Equity Investment Fund Center holds 1.99% of the shares.
Waterwood Tactics持股为1.66%，Martrix Partners China II（经纬中国）持股2.98%，Martrix Partners China II-A持股0.33%，北京明启企业旗下Waterwood DHC（富德生命）持股为12.58%；中金康瑞壹期（宁波）股权投资基金合伙持股为3.32%。
———————————————
Lei Di was founded by Lei Jianping, a media person, if it is reprinted, please indicate the source.